MX2016006256A - Tratamiento de glaucoma usando laquinimod. - Google Patents

Tratamiento de glaucoma usando laquinimod.

Info

Publication number
MX2016006256A
MX2016006256A MX2016006256A MX2016006256A MX2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A
Authority
MX
Mexico
Prior art keywords
subject
glaucoma
damage
iop
loss
Prior art date
Application number
MX2016006256A
Other languages
English (en)
Spanish (es)
Inventor
Neumann Ron
ETZYONI Revital
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2016006256A publication Critical patent/MX2016006256A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • B65D1/0207—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016006256A 2013-11-15 2014-11-13 Tratamiento de glaucoma usando laquinimod. MX2016006256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904962P 2013-11-15 2013-11-15
PCT/US2014/065497 WO2015073697A1 (en) 2013-11-15 2014-11-13 Treatment of glaucoma using laquinimod

Publications (1)

Publication Number Publication Date
MX2016006256A true MX2016006256A (es) 2016-09-07

Family

ID=53058023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006256A MX2016006256A (es) 2013-11-15 2014-11-13 Tratamiento de glaucoma usando laquinimod.

Country Status (12)

Country Link
US (6) US20150141458A1 (enExample)
EP (1) EP3068395A4 (enExample)
JP (1) JP2016537364A (enExample)
KR (1) KR20160100302A (enExample)
CN (1) CN105960238A (enExample)
AU (1) AU2014348620A1 (enExample)
CA (1) CA2930113A1 (enExample)
EA (1) EA201690903A1 (enExample)
HK (1) HK1225971A1 (enExample)
IL (1) IL245373A0 (enExample)
MX (1) MX2016006256A (enExample)
WO (1) WO2015073697A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019182814A (ja) * 2018-04-17 2019-10-24 国立大学法人九州大学 生体リズム調整剤及び生体リズム調整用医薬組成物
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
EP3888650A1 (en) * 2020-03-30 2021-10-06 Universität Regensburg Biochanin a diacetate for treatment of best1-related retinopathies
AU2022248724A1 (en) * 2021-04-01 2023-11-02 Active Biotech Ab Laquinimod formulation for ocular use
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
SG10201606191PA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病

Also Published As

Publication number Publication date
US20170266179A1 (en) 2017-09-21
AU2014348620A1 (en) 2016-06-16
KR20160100302A (ko) 2016-08-23
IL245373A0 (en) 2016-06-30
US20180140593A1 (en) 2018-05-24
US20170368054A1 (en) 2017-12-28
US20170128436A1 (en) 2017-05-11
EA201690903A1 (ru) 2016-10-31
US20150141458A1 (en) 2015-05-21
EP3068395A4 (en) 2017-07-12
EP3068395A1 (en) 2016-09-21
WO2015073697A1 (en) 2015-05-21
CA2930113A1 (en) 2015-05-21
JP2016537364A (ja) 2016-12-01
HK1225971A1 (zh) 2017-09-22
US20170027927A1 (en) 2017-02-02
CN105960238A (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
PH12020551427A1 (en) Epinephrine spray formulations
NZ704247A (en) Compositions and treatment for eye diseases and disorders
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
EP4324454A3 (en) Cross-linking agents and associated methods
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201390364A1 (ru) Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2019008621A (es) Peptidos terapeuticos y neuroprotectores.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
BR112015022044A2 (pt) um método de proporcionar neutroproteção ocular
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX342930B (es) Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy